StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research note published on Tuesday morning. The firm issued a sell rating on the stock.

Separately, Lake Street Capital began coverage on InspireMD in a research report on Wednesday, December 11th. They set a “buy” rating and a $5.00 price target on the stock.

InspireMD Price Performance

NYSE NSPR opened at $2.75 on Tuesday. The stock’s fifty day moving average price is $2.86 and its 200 day moving average price is $2.76. InspireMD has a 1 year low of $1.81 and a 1 year high of $3.80. The company has a market cap of $81.65 million, a price-to-earnings ratio of -3.67 and a beta of 0.88.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Parkman Healthcare Partners LLC lifted its stake in InspireMD by 721.2% in the 4th quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company’s stock worth $2,248,000 after purchasing an additional 750,635 shares in the last quarter. Essex Investment Management Co. LLC acquired a new position in InspireMD in the fourth quarter valued at approximately $191,000. Northern Trust Corp raised its position in InspireMD by 103.7% in the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock valued at $126,000 after purchasing an additional 24,452 shares during the period. Schonfeld Strategic Advisors LLC raised its position in InspireMD by 153.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock valued at $79,000 after purchasing an additional 18,233 shares during the period. Finally, Legato Capital Management LLC purchased a new stake in InspireMD in the fourth quarter valued at approximately $47,000. 44.78% of the stock is owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.